Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: Application to carvedilol stereopharmacokinetics
- 1 January 1993
- Vol. 5 (1), 1-7
- https://doi.org/10.1002/chir.530050102
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Assay and Disposition of Carvedilol Enantiomers in Humans and Monkeys: Evidence of Stereoselective Presystemic MetabolismJournal of Pharmaceutical Sciences, 1990
- Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compoundEuropean Journal of Clinical Pharmacology, 1990
- The pharmacology of carvedilolEuropean Journal of Clinical Pharmacology, 1990
- Measurement of Carvedilol Enantiomers in Human Plasma and Urine Using S‐Naproxen Chloride for Chiral DerivatizationArchiv der Pharmazie, 1990
- Identification of two major biliary metabolites of carvedilol in ratsXenobiotica, 1990
- Studies on the metabolic fate of carvedilol. (III). Biliary excretion and enterohepatic circulation in rats.Drug Metabolism and Pharmacokinetics, 1989
- Pharmacokinetics and Bioavailability of Carvedilol in Patients with Liver CirrhosisDrugs, 1988
- Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blockerEuropean Journal of Clinical Pharmacology, 1987
- Pharmacokinetics and Disposition of Carvedilol in HumansJournal of Cardiovascular Pharmacology, 1987
- Stereoselectivity in the metabolism of the .BETA.-adrenergic blocking agent, (.+-.)-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride (xibenolol hydrochloride, D-32), in man.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985